Novel techniques of percutaneous sonography-guided surgical operations (SonoSurgery

一家名为Spirecut的瑞士公司开发了一种创新的方法来治疗腕管和扳机指，该方法使用专利仪器（Sono-Instruments）和一种在超声波下进行的无切口技术。患者可以在10分钟内在门诊接受治疗，无需缝合，可以立即恢复正常活动。在当前的气候下，由于NHS资源紧张，常规手术等待名单不断增加（NHS等待名单上有超过700万人），这种新技术有可能降低成本，提高NHS效率，让患者更快地重返工作岗位，从而帮助新冠疫情后的经济。在这个项目中，一个英国-瑞士合作团队将努力将Spirecut方法扩展到其他患者群体。Sono-Instruments的英国分销商、南安普顿大学的Sovereign Medical和健康经济学家将与瑞士的Spirecut合作，研究将这项技术扩展到其他疾病，如Dupuytren病、De Quervain病和网球肘。Sovereign Medical将牵头招募一个由英国和瑞士联合组成的专家顾问小组，其中包括骨科医生和介入放射科医生，他们将评估Spirecut技术在这些额外用途中的适用性。咨询小组在德尔菲演习中与更广泛的临床医生小组进行的审议和协商将用于评估潜在适应症的技术可行性，以及采用这些技术将对保健服务和医疗创新产生的经济影响。南安普顿大学的卫生经济团队将开发一个模型，以帮助进一步研究和投资的决策。该模型将从商业角度对每种指标的市场价值进行估计，并对NHS的预算影响和成本效益进行估计。这些估计将基于已发表的信息、真实证据来源和专家意见，并将随着瑞士临床研究的结果而更新。这将为将来提交给国家健康和护理卓越研究所（NICE）提供基础，目的是获得采用NHS的建议。

A Swiss company, Spirecut, has developed an innovative way to treat carpal tunnel and trigger finger using patented instruments (Sono-Instruments) and an incisionless technique conducted under ultrasound. Patients can be treated in an outpatient clinic in under 10 minutes, with no stitches and can resume normal activities immediately. In the current climate, with great strain on NHS resources and growing waiting lists for routine operations (over 7 million on NHS waiting list), this novel technique has the potential to reduce costs, improve NHS efficiency and get patients back to work faster, helping the economy post Covid. In this project, a collaborative UK-Swiss team will work to extend the Spirecut approach to other patient groups.The UK distributor of the Sono-Instruments, Sovereign Medical and health economists at the University of Southampton will work in partnership with Spirecut in Switzerland to conduct research on the extension of this technology for other conditions, such as Dupuytren disease, De Quervain and tennis elbow. Sovereign Medical will lead on recruiting to a joint UK-Swiss panel of expert advisors, including orthopaedic surgeons and interventional radiologists, who will assess suitability of the Spirecut technology these additional uses. The advisory group deliberations and consultations with a wider group of clinicians in a Delphi exercise will be used to assess the technical feasibility of the potential indications, and the economic impact that adopting these techniques would have on health services and medical innovation.The health economic team at Southampton will develop a model to aid decision making about further research and investment. The model will provide estimates of market value for each indication from a commercial perspective and estimates of budget impact and cost-effectiveness for the NHS. These estimates will be based on published information, real-world evidence sources and expert opinion, and will be updated as results from the Swiss clinical studies become available. This will provide a foundation for a future submission to the National Institute for Health and Care Excellence (NICE) with the aim of obtaining a recommendation for NHS adoption.